Kornimate/medical-research-clean huggingface dataset:
physical activity in the treatment of obesity

Conditions: Obesity

Summary: although exercise is widely regarded as a key component in obesity treatment, few individuals seem able to adhere to exercise programs over time. in response, efforts have focused on developing new approaches to physical activity that may appeal to sedentary overweight persons. for instance, is has been shown that accumulating multiple short bouts of vigorous exercise may enhance both exercise adherence and weight loss in overweight persons. accumulating moderate-intensity activity throughout the day may offer comparable health and weight benefits as a traditional exercise program. public health recommendations now include the option of accumulating 30 minutes of moderate-intensity lifestyle activity for health and well-being. while these two options offer a viable alternative to those who dislike or cannot sustain continuous vigorous exercise programs, it is unclear whether the flexibility of accumulating physical activity or the vigorous intensity of the exercise is responsible for improved weight loss and long-term adherence. the goal of this research is to extend our preliminary findings suggesting that moderate intensity lifestyle activity is an important and viable alternative to traditional structured vigorous exercise for obese dieting individuals. the primary specific aim of this project is to compare the effects of three modes of exercise on long-term weight regain. participants will be 165 overweight men and women who are sedentary, but otherwise healthy. all participants will receive the same 16-week behavioral weight loss program and will be randomized to one of three exercise study conditions: 1) diet-plus-continuous bouts of vigorous aerobic exercise; 2) diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day; or 3) diet-plus-moderate intensity lifestyle activity accumulated throughout the day. by varying both the intensity and duration of exercise bouts, we can determine which type of exercise is associated with optimal outcomes one year later. additional questions of interest include: 1. does mode of exercise influence exercise adherence? 2. does mode of exercise improve cardiovascular risk profiles similarly in all three conditions? 3. does mode of exercise influence changes in body composition? 4. does mode of exercise influence exercise enjoyment and exercise self-efficacy?


Eligibility criteria:
inclusion criteria:sedentary and \>30 pounds above healthy weight. no plans to move from area for next 1.5 years. no plans for excessive travel. - exclusion criteria: recent weight loss or regular exercise (≥2 bouts per week), serious medical or psychiatric condition (cardiovascular, metabolic or orthopedic) or history of clinical depression or eating disorder. -

Keywords: overweight, physical activity, body composition, metabolic syndrome
detection and classification of cardiac rhythm and atrial fibrillation using a finger-worn ring

Conditions: Atrial Fibrillation (AF); Arrhythmias Cardiac; Tachycardia; Palpitations; Bradycardia

Summary: everbeat is a finger-worn ring that has a built-in electrocardiogram (ecg). in this study the investigators ensure that the ecg as read by the everbeat correctly classifies heart rhythms and detects atrial fibrillation. investigators will also correlate the everbeat ecg waveform with a clinical-grade fda approved electrocardiogram to ensure it may be reliably interpreted by clinicians or other algorithms.

in this study the participant will obtain a simultaneous electrocardiogram from both the everbeat ring system and a clinical-grade diagnostic ecg machine for correlation and analysis.

Eligibility criteria:
inclusion criteria: * 18 years of age or older exclusion criteria: * presence of pacemaker or defibrillator * inability to wear a ring in size range available

Keywords: atrial fibrillation wearable monitor electrocardiogram ring
comparative pharmacokinetics study of clopidogrel and aspirin fixed-dose combination versus separate combination

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.


Eligibility criteria:
inclusion criteria: * a healthy male volunteer aged 20 to 55, and within 20% of ideal body weight. * have not any congenital or chronic diseases and medical symptom. * appropriate subject for the study judging from examinations(interview, vital signs, 12-lead ecg, physical examination, blood, urinalysis result on screening. * able to participate in the entire trial. * signed the informed consent form prior to study participation. exclusion criteria: * take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days prior to the first ip administration. * show evidence of acute disease within 28 days prior to the first ip administration. * have the medical history of bleeding symptom or bleeding disease * have the disease history(ex. inflammatory intestinal disease, stomach or duodenum ulcer, liver and bowels disease, appendectomy except of gastrointestinal surgery history) that may influence on the absorption, distribution, metabolism and excretion of the drug. * have relevant hypersensitivity against drug or clinically significant allergic diseases except mild rhinitis that does not need medication. * have hypersensitivity reaction histories for clopidogrel or aspirin. * have abnormal laboratory result. ast or alt \> 1.25 times of upper limit/ total bilirubin \> 1.5 times of upper limit/ pt, aptt, bt over upper limit/ platelet count \ 350x10\^9/l * a drug abuse or a heavy caffeine consumer (more than 5cups per a day) or a heavy smoker (more than 10 cigarettes per a day) or a regular alcohol consumer(more than 30g/day) or drinking within 7days prior to the first ip administration. * have a diet(especially, grapefruit juice-within 7days prior to the first ip administration) that may influence on the absorption, distribution, metabolism and excretion of the drug(s). * have donated whole blood within 60 days prior to the first ip administration. * participated in the other clinical trials within 90days prior to the first ip administration. * take medicine which affect to this trial within 10 days prior to the first ip administration. * appropriate subject for the trial judging from principal investigator.

Keywords: clopidogrel aspirin combination pharmacokinetics phase 1
modeling treated recovery from aphasia

Conditions: Aphasia; Stroke; Stroke, Ischemic; Aphasia, Broca; Aphasia, Global; Aphasia, Mixed; Aphasia, Jargon; Aphasia, Expressive; Aphasia, Conduction; Aphasia, Fluent; Aphasia, Anomic

Summary: stroke is the leading cause of adult disability in the united states, and aphasia is common following a stroke to the left hemisphere of the brain. aphasia therapy can improve aphasia recover; however, very little is known about how different patients respond to different types of treatments. the purpose of this study is to understand how the following factors influence an individual's response to aphasia treatment: 1) biographical factors (e.g., age, education, gender), 2) post-stroke cognitive/linguistic abilities and learning potential, and 3) the location and extent of post-stroke brain damage. we are also interested in understanding the kinds of treatment materials that should be emphasized in speech/language treatment. overall, the goal of the current research is to inform the clinical management of post-stroke aphasia by identifying factors that can predict how an individual will respond to different treatment methods.


Eligibility criteria:
inclusion criteria: * experienced a left hemisphere ischemic or hemorrhagic stroke at least 12 months post-stroke * primarily english speaker for the past 20 years * ability to provide informed written or verbal consent mri-compatible (e.g., no metal implants, not claustrophobic) exclusion criteria: * history of a right hemisphere stroke (bilateral stroke) * clinically reported history of dementia, alcohol abuse, psychiatric disorder, traumatic brain injury, or extensive visual acuity or visual-spatial problems * severely limited speech production and/or auditory comprehension that interferes with adequate participation in the therapy provided
nutritional supplement for treating chemotherapy induced neuropathy

Conditions: Cancer; Neuropathy; Chemotherapy Induced Pain Neuropathy; Chemotherapy-Induced Peripheral Neuropathy

Summary: administration of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin b12, vitamin b6 , vitamin b1, nicotinamide, magnesium, zinc, vitamin e, and superoxide of dismutase in individuals receiving chemotherapy

investigation of effectiveness and safety of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin b12, vitamin b6 , vitamin b1, nicotinamide, magnesium, zinc, vitamin e, and superoxide of dismutase in individuals receiving chemotherapy

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with cancer that have not received yet their treatment * patients that will be treated with platinum agents or taxanes exclusion criteria: * not receiving dietary supplement * have already neuropathy * have already started chemotherapy * patients with uncontrolled diabetes -- patients with chronic kidney disease * patiens with recent cardiovascular incident

Keywords: cancer neuropathy chemotherapy induced neuropathy supplement
effects of betaserc on vestibular compensation in patients suffering from disabling meniere's disease and having undergone vestibular neurotomy

Conditions: Meniere's Disease

Summary: this study is to compare the effects of betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling menière's disease.


Eligibility criteria:
inclusion criteria: * patients who have undergone vestibular neurotomy for the treatment of disabling menière's disease and who have confirmed vestibular areflexia exclusion criteria: * other peripheral vestibular disease than menière's disease * central vestibular disease * neurological disease * contraindication to betahistine * pregnant or lactating women

Keywords: meniere's disease vestibular neurotomy
efficacy and safety study of drugs for treatment of visceral leishmaniasis in brazil

Conditions: Visceral Leishmaniasis

Summary: this study is aimed to compare the efficacy and safety of medications currently used in brazil for treatment of visceral leishmaniasis. the investigators will compare the effects of meglumine antimoniate, two formulations of amphotericin b: deoxycholate and liposomal, and a combination of meglumine plus the liposomal amphotericin b formulation. the study is designed to demonstrate the difference in efficacy measured as cure rate at six months after treatment and the safety profile based on the adverse event rate observed with each intervention.

visceral leishmaniasis is a relevant public health problem in brazil with approximately 3500 cases registered every year. eight percent lethality rate has been observed during the past decade in spite of free of charge availability of antileishmanial drugs supplied by the public health system. the present study was designed as a phase iv, multicentric, open label, active controlled clinical trial targeted to visceral leishmaniasis adult and pediatric cases. the current drugs approved for visceral leishmaniasis treatment in brazil will be compared in four treatment groups: meglumine antimoniate, amphotericin b deoxycholate, liposomal amphotericin b and a combination of single dose of liposomal amphotericin b plus meglumine antimoniate. meglumine antimoniate treated patients will constitute the active control group. drugs will be compared based on the cure rate observed after six months follow-up. the study arm submitted to treatment with amphotericin b deoxycholate was suspended in september 2012.

Eligibility criteria:
inclusion criteria: * patients with visceral leishmaniasis characterized by fever plus hepatomegaly or splenomegaly with at least one positive result in the following laboratory tests: * direct observation of leishmania amastigotes in bone marrow smear * leishmania in vitro culture from bone marrow aspirates * leishmania kdna amplification by pcr in bone marrow or peripheral blood samples * rk39 immunochromatographic rapid test performed on serum sample exclusion criteria: * pregnancy * hiv infection * chronic diseases such as diabetes mellitus,kidney, liver or cardiac diseases, schistosomiasis, malaria or tuberculosis * immune disorders or use of drugs which interferes with the immune response * treatment with drugs with increased risk for toxicity associated with the study drugs * exposure to antileishmanial drugs during the past six months * i.v. drug users * episodes of visceral leishmaniasis relapse * hypersensibility to the study drugs * difficulties for accomplishing the follow-up schedule * any of the following clinical signs of laboratory abnormalities: hepatic encephalopathy, generalized edema, toxemic individuals, severe malnutrition, jaundice, abnormal serum creatinine, bilirubin, inr \> 2,0, platelet count \< 20000/mm3

Keywords: visceral leishmaniasis leishmania infantum leishmania chagasi
relationship between stress, anxiety, depression, sexual function and marital adjustment in nurses

Conditions: Stress; Anxiety Disorders; Sexual Behavior

Summary: one of the factors that increase harmony in marriage is sexual life and sexual satisfaction (erdinç, 2018). sexual intercourse is one of the pillars of a successful family; accordingly, functionality in this area greatly affects marital adjustment (atrian, 2018). studies show an important relationship between sexual adjustment and marital adjustment (türkseven et al., 2020; begdeş, 2021). negative workplace factors such as occupational stress and long working hours affect the physical and mental states of nurses (oyeleye et al., 2013; chesak et al., 2019). this study was planned to determine the relationship between stress, anxiety, depression, sexual function and marital adjustment in nurses.


Eligibility criteria:
inclusion criteria: * volunteer to participate in the research, * over the age of 18, * married, * those whose spouse is alive and living with their spouse will be included. exclusion criteria: * having a chronic disease (hypertension, diabetes), * nurses who are pregnant, * those who use drugs that may affect sexual function (beta-blockers, antihypertensives, antidepressants, antipsychotics, etc.) will be excluded from the study.
safety study of nbp608 in healthy adult volunteers

Conditions: Varicella Zoster; Immunization; Infection

Summary: * indication: protection against varicella and herpes zoster * study objectives * primary: safety and tolerability assessment after single dose administration of nbp608 * secondary: immunogenicity assessment after single dose administration of nbp608

this is a single-center, open label, active controlled, dose-escalation, parallel group study to assess the safety, tolerability and immunogenicity of nbp608 in healthy adult volunteers. total of 150 healthy subjects aged 20 and over are enrolled, and each subject is administered with single dose of vaccine which is sequentially assigned to active group 1, 2 and study group 1\~3 in 1:1:1:1:1 ratio(30 subjects are enrolled at each groups) .

Eligibility criteria:
inclusion criteria: * healthy adults aged 20 and over * availability to volunteer for the entire study duration and willing to adhere to all protocol requirements * female subjects of post-menopausal (amenorrhea for 24 months) whose pregnancy tests was found negative at screening visit * subjects of seropositive for varicella-zoster virus at screening visit exclusion criteria: * patients with herpes zoster * subjects with a history of vaccination for herpes zoster * pregnant or lactating women * participants in another clinical study within 4 weeks before vaccination in this study, etc.

Keywords: varicella vaccine herpes zoster vaccine
a prospective, randomized, multicenter study to demonstrate the superiority of the barricaid to discectomy for primary lumbar disc herniation

Conditions: Lumbar Disc Herniation

Summary: a randomized study to demonstrate the superiority of the barricaid® when used in conjunction with limited discectomy, compared to limited discectomy alone, with regard to preventing reherniation and the recurrence of pain or dysfunction.

the barricaid is indicated for patients with radiculopathy (with or without back pain), a positive straight leg raise (l45, l5s1) or femoral stretch test (l12, l23, l34), and a posterior or posterolateral herniation at one level between l1 and s1 with radiographic confirmation of neural compression using mri who are found to have an annular defect (post discectomy) which measures between 4mm and 6mm tall and between 6mm and 10mm wide, have a minimum posterior disc height of 5mm, and have failed at least 6 weeks of conservative treatment including a post-approval amendment with follow-up visits at 7 \& 10 years for eligible subjects.

Eligibility criteria:
inclusion criteria: * age 21 to 75 years old and skeletally mature (male or female). * patients with posterior or posterolateral disc herniations at one level between l1 and s1 with radiographic confirmation of neural compression using magnetic resonance imaging (mri). * at least six (6) weeks of failed, conservative treatment prior to surgery * oswestry disability index (odi) questionnaire score of at least 40/100 at baseline. * visual analog scale (vas) leg pain (one or both legs) of at least 40/100 at baseline. * psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements. exclusion criteria: * spondylolisthesis grade ii or higher (25% slip or greater). * prior surgery at the index lumbar vertebral level. * subject has scoliosis of greater than ten (10) degrees (both angular and rotational). * any metabolic bone disease. * subject has insulin-dependent diabetes mellitus. * subject has been diagnosed with active hepatitis, acquired immunodeficiency syndrome (aids), or human immunodeficiency virus (hiv). * subject has been diagnosed with rheumatoid arthritis or other autoimmune disease. * subject has a known allergy to titanium, polyethylene or polyester materials. * any subject that cannot have a baseline mri taken. * subject is pregnant or interested in becoming pregnant in the next three (3) years. * subject has active tuberculosis or has had tuberculosis in the past three (3) years. * subject is currently involved in another investigational study. * any contraindication for mri or computed tomography ct scan (e.g. claustrophobia, contrast allergy).
study in post-menopausal women with hormone receptor positive, her2-negative advanced breast cancer

Conditions: Post Menopausal Breast Cancer

Summary: this international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with hr positive, her2 negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitors (nsai) therapy in novartis oncology emergent growth market (egm) countries.data was presented by asian countries vs non-asian countries to confirm no difference in safety and efficacy. summary statistics were presented.


Eligibility criteria:
inclusion criteria: * postmenopausal women with metastatic, recurrent or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy. * histological or cytological confirmation of hormone-receptor positive (hr+) breast cancer. * disease refractory to non-steroidal aromatase inhibitors, defined as: * recurrence while on, or within 12 months (365 days) of completion of adjuvant therapy with letrozole or anastrozole, or * progression while on, or within one month (30 days) of completion of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer (abc). * radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrolment. * patients must have had: * at least one lesion that could have been accurately measured in at least one dimension * 20 mm with conventional imaging techniques or ≥ 10 mm with spiral ct or mri, or * bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above. * adequate bone marrow, coagulation, liver and renal function. * ecog performance status ≤ 2. exclusion criteria: * patients overexpressing her2 by local laboratory testing (ihc 3+ staining or in situ hybridization positive). patients with ihc 2+ must have a negative in situ hybridization test. * patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites). * patients with more than one prior chemotherapy line for abc. a chemotherapy line is an anticancer regimen(s) that contained at least 1 cytotoxic chemotherapy agent, given for a minimum of 21 days. * previous treatment with mtor inhibitors. * known hypersensitivity to mtor inhibitors, e.g. sirolimus (rapamycin). * patients with a known history of hiv seropositivity. screening for hiv infection at baseline was not required. * patient who were being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cyp3a * history of brain or other cns metastases, including leptomeningeal metastasis.

Keywords: post menopausal advanced breast cancer metastatic breast cancer everolimus exemestane mtor inhibitor endocrine therapy human epidermal growth factor estrogen receptor positive adult crad001
visual perceptual motor training on kindergarteners

Conditions: Agraphia

Summary: the study aims to investigate the effects of different visuomotor training programs on children's visuomotor skills and handwriting performance.

the purpose of this project is to investigate the effectiveness of visuomotor activities with different activity materials on fine motor, visual perception, visual-motor integration and handwriting performance of kindergarten children. kindergarteners will be randomized into the three groups: control, chinese, and traditional groups. children in the chinese and traditional groups will receive a visual perceptual motor training program twice every week for 12 weeks and those in the control group will not receive any intervention during the study period. in the end of fall semester of the first grade, the effectiveness of the interventional programs on handwriting performance of participants will be examined again.

Eligibility criteria:
inclusion criteria: * kindergarten children who will study the first grade in coming september * both parents are native mandarin chinese speakers exclusion criteria: * a diagnosis of significant neurological, muscular, and skeletal system disorders * visual or hearing problems that cannot be corrected to be normal * genetic or chromosomal abnormality * significant neurological, muscular, and skeletal damage to the trunk or upper extremities * moderate or severe intellectual disabilities

Keywords: visual kindergarten chinese